Asking Price Contact for pricing
Area Size
NOI Net Operating Income N/A
Cap Rate N/A

Documents

I accept the confidentiality agreement
Create an account on the Investor Center to save your search and investment preferences, save and share opportunities, access exclusive documents, and more. More questions? Visit our FAQ. Approval for Deal Room access requires review by our Broker Team. You will be notified by email once your access is granted. More questions? Visit our FAQ. You'll need to sign a Confidentiality Agreement (CA) to access exclusive documents in the Deal Room. Signing the CA means you agree not to divulge or release sensitive information related to this property. More questions? Visit our FAQ.
I accept the confidentiality agreement I accept the confidentiality agreement
Create an account on the Investor Center to save your search and investment preferences, save and share opportunities, access exclusive documents, and more. More questions? Visit our FAQ. You'll need to sign a Confidentiality Agreement (CA) to access exclusive documents in the Deal Room. Signing the CA means you agree not to divulge or release sensitive information related to this property. More questions? Visit our FAQ.

Key facts

Year Built 1958
Building Area Net
Land Area Net ()
Rentable Area
Occupancy 93.0 %

Property description

Jones Lang LaSalle Americas, Inc. (“JLL”), has been retained on an exclusive basis to arrange the sale of ArborRidge (the “Property”), a three-building, life sciences conversion opportunity. Totaling 128,627 square feet, the Property is located in the heart of the Main Line’s Route 202 lab corridor, Philadelphia’s suburban life sciences hub with over 35% of the region’s lab space. ArborRidge provides investors with a rare value-add opportunity to acquire a superbly positioned property for a future lab conversion.


The Property offers impressive existing infrastructure critical for lab and research operations rarely seen in an adaptive re-use opportunity. Namely, its high level of current finish, generous ceiling height, and one- and two-story configuration, give an operator a meaningful head-start to attract life sciences users. Additionally, two current tenants currently have lab space at the Property, Eggland’s Best (Testing Lab) and VenatoRx (Chem Lab), providing proof of concept for the buildings and location.

Investment highlights

ULTRA PREMIUM LAB CONVERSION

  • JLL consulted with an international leader in MEP design to review the physical condition of ArborRidge and its ability to be converted to research and development uses. The Property offers impressive existing infrastructure critical for lab and research operations, rarely seen in an adaptive re-use opportunity.

PROPOSED FUTURE DEVELOPMENT & EXPANSION

  • The southern-most portion of the parcel contains additional developable land. This allows investors to market ArborRidge to a wide variety of life sciences tenants. The asset can accommodate tenants seeking immediate occupancy by converting existing office space in the buildings or those tenants with customized ground-up or single user needs.

RAPIDLY EXPANDING LIFE SCIENCES MARKET

  • The Philadelphia region shattered its previous life sciences venture capital record with nearly $1.9 billion invested in local companies in 2021. The region’s recent growth in funding (350% since 2015) is the second fastest VC growth rate nationally, behind the New York area. Furthermore, based on Life Sciences VC funding from the first quarter of 2022, the region is on track to exceed 2021 numbers. 
Last Updated Date: 11 Aug 2022

There was an error submitting your request. Please try again, or submit you inquiry here.

 

PRIVACY NOTICE

JLL, together with its subsidiaries and affiliates, is a leading global provider of real estate and investment management services. We take our responsibility to protect the personal information provided to us seriously.

Generally the personal information we collect from you are for the purposes of dealing with your enquiry.

We endeavor to keep your personal information secure with appropriate level of security and keep for as long as we need it for legitimate business or legal reasons. We will then delete it safely and securely. For more information about how JLL processes your personal data, please view our privacy statement.

Last Updated Date: 11 Aug 2022

Do you have any questions?  Visit our FAQ page

JLL  financing

JLL can help you finance and manage your portfolio.
Email us today to see how we can help achieve your ambitions.